statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Investors might want to bet on Rocket Pharmaceuticals (NASDAQ: RCKT), as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful...

Rocket Pharmaceuticals Upgraded to Buy: Here's Why

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today...

Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Mirum Pharmaceuticals (MIRM Research Report) and Rocket Pharmaceuticals...

Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (MIRM) and Rocket Pharmaceuticals (RCKT)

Rocket Pharmaceuticals (RCKT) has shared an announcement. Rocket Pharmaceuticals, Inc. has appointed Aaron Ondrey as their new Chief Financial Offi...

Rocket Pharmaceuticals Welcomes New CFO Aaron Ondrey

This is a signal that RCKT's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options...

Rocket Pharmaceuticals (RCKT, $26.92) Stochastic Oscillator left the oversold zone on March 28, 2024

Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT  Get Free Report) Director Gotham Makker sold 274,000 shares of the stock in a transaction dated Thursday, March 21st. The stock was sold at an...

Insider Selling: Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Director Sells 274,000 Shares of Stock

This indicator may be signaling RCKT's price has momentum to move higher, since its current price moved above its price 14 days ago. Traders may consider buying the stock or exploring call options...

Rocket Pharmaceuticals (RCKT, $27.86) entered Uptrend as Momentum indicator ascends above 0 level on Mar 20, 2024

Rocket Pharmaceuticals (RCKT, $27.86) Stochastic Oscillator left the oversold zone on March 20, 2024

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT  Get Free Report) insider John Militello sold 10,000 shares of the stock in a transaction dated Thursday, February 29th. The shares were sold at an...

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Insider John Militello Sells 10,000 Shares

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms. Its clinical program is an LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded on July 7, 1999 and is headquartered in Cranbury, NJ.

Volume	630,425.00
52-Wk High	$32.53
52-Wk Low	$14.89

Period	Estimated	Reported	Surprise	Result
Q1'24	-$0.67	--	--	N/A
Q4'23	-$0.78	-$0.64	17.79%	BEAT
Q3'23	-$0.81	-$0.75	7.88%	BEAT
Q2'23	-$0.81	-$0.82	-1.40%	MISSED
Q1'23	-$0.83	-$0.73	11.91%	BEAT

RCKT Rocket Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals